4.1 Article

Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP)

期刊

ANNALES D ENDOCRINOLOGIE
卷 84, 期 6, 页码 697-710

出版社

MASSON EDITEUR
DOI: 10.1016/j.ando.2023.08.003

关键词

Acromegaly; Consensus; Guidelines; Recommendations; Guidance; Position statement; Pituitary surgery; Somatostatin analogues; Pasireotide; Cabergoline; Pegvisomant; Growth hormone; Somatotroph adenoma; Pituitary neuroendocrine tumor; Acromegalic arthropathy; Treatment; Diagnosis and care protocol

向作者/读者索取更多资源

Acromegaly is a rare disease with a slight female predominance and peak onset in adults in the fourth decade. The clinical diagnosis is often delayed due to the slowly progressive onset of symptoms. Multiple clinical criteria define acromegaly, and imaging by pituitary MRI is used to identify the causal tumor for better management. Surgical removal of the tumor is the first-line treatment, with medical treatments used when surgery is not effective. In some cases, acromegaly may be linked to a genetic predisposition.
Acromegaly is a rare disease with prevalence of approximately 60 cases per million, slight female predominance and peak onset in adults in the fourth decade. Clinical diagnosis is often delayed by several years due to the slowly progressive onset of symptoms. There are multiple clinical criteria that define acromegaly: dysmorphic syndrome of insidious onset, symptoms related to the pituitary tumor (headaches, visual disorders), general signs (sweating, carpal tunnel syndrome, joint pain, etc.), complications of the disease (musculoskeletal, cardiovascular, pneumological, dental, metabolic comorbidities, thyroid nodules, colonic polyps, etc.) or sometimes clinical signs of associated prolactin hypersecretion (erectile dysfunction in men or cycle disorder in women) or concomitant mass-induced hypopituitarism (fatigue and other symptoms related to pituitary hormone deficiencies). Biological confirmation is based initially on elevated IGF-I and lack of GH suppression on oral glucose tolerance test or an elevated mean GH on repeated measurements. In confirmed cases, imaging by pituitary MRI identifies the causal tumor, to best determine management. In a minority of cases, acromegaly can be linked to a genetic predispo-sition, especially when it occurs at a young age or in a familial context. The first-line treatment is most often surgical removal of the somatotroph pituitary tumor, either immediately or after transient medical treatment. Medical treatments are most often proposed in patients not controlled by surgical removal. Conformal or stereotactic radiotherapy may be discussed on a case-by-case basis, especially in case of drug inefficacy or poor tolerance. Acromegaly should be managed by a multidisciplinary team, preferably within an expert center such as a reference or skill center for rare pituitary diseases. (c) 2023 Published by Elsevier Masson SAS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据